Page 23 - 10 Most Trusted Diagnostic Companies in India 2022

COVER STORY

• Similarly, when it comes to So this has become an extremely GROWTH PATH Our growth path is very well laid out

popping a pill in your mouth it significant product for MKPPL for MKPPL, in these years, has moved and I think you will hear a lot more

involves a lot of queries, a lot of COPD treatment. COPD it’s a life- from being a formulation interme- about MKPPL in the near future I
questions, a lot of compliances and time disease and if you are going

all these cost money. from regula- to continue giving High dosages, diate to finish formulation manu- hope it’s all going to be good news.
tory compliance to developments it is going to be tough for the facturers which will lead us further. We expect to be number one in

and Innovation, at every step, you’re We are not only looking at making this Niche pharmaceutical range.
talking about money. In a nutshell, concerned individual so we require finished dosage forms of the regular We look forward to being a good

a lot of Investments are required in a lower dosage for better treat- drugs available in the marketplace,

this industry and in 2020, MKPPL ment. We are going ahead with but also making finish formulations innovative company. Dreams are
got a massive investment from registering our product in India. of innovative products and hence many, the pathways are long and

InvAscent, a.k.a India Lifesciences there is no time to sleep because

based on our industrial innovations. • Next, we have an ophthal- entering into a new niche. This we are in the most interesting
Everyone was aware that 2020 was mology product to treat glau- area is what will position MKPPL

the peak year of covid-19 and that coma. The majority of OTC glau- from being a small small-sized and the most exciting part of
was the period where investment coma ophthalmic drugs fall more company to a Mid-Cap company our business and I think we are

stopped world across. MKPPL was out of the eye than stay in the eye. and further a Blue-chip company. going to grow the right way.
among the very few companies The human eye has a lipophilic

that got massive investments at layer that protects the cornea

that time. InvAscent invested in our from any foreign object going into
potential and capabilities and the the eye, hence throwing out the

product pipeline that will take us to drugs as well. So when you reduce
the next level. What they came in

for is what is happening at MKPPL. the particle size of the drug,
you are ensuring better absorp-
• Our Transdermal oil is going in a tion of the drug into the cornea
very big way. and thereby reducing glaucoma.

• We also have our Nano mist or the

soft mist of budesonide which by • We have utilized our technology

itself is a specialized product. If you advancements even in Oncology
are giving a normal product vs. our and regular dosage drugs.

product, you’re giving 1/20th of the “We can say that Innovation

dosage and the product deposits flows in our DNA.”
itself very evenly on the alveoli.

|22 thecorporatereview.com | India | Vol. 3 | Issue 3 | March 2022 |23